Software as a Medical Device Market Summary

• The global software as a medical device market was valued at USD 2.10 billion in 2025 and is projected to reach USD 8.90 billion by 2034.
• The market is expected to expand at a CAGR of 17.4% during the forecast period 2026-2034, supported by the integration of artificial intelligence and machine learning into clinical software, the growth of digital therapeutics and remote care, the maturation of regulatory pathways for software and adaptive algorithms, and the demand for diagnostic and decision support that improves care.
• By type, the diagnostic and screening software segment dominated the software as a medical device market with a 42% share in 2025.
• By application, the radiology and medical imaging segment dominated the software as a medical device market with a 34% share in 2025.
• By deployment, the cloud-based segment dominated the software as a medical device market with a 62% share in 2025.
• By end-user, the hospitals and clinics segment dominated the software as a medical device market with a 54% share in 2025.
• North America accounted for the largest share of the software as a medical device market at 45% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

Software as a medical device is software intended to be used for one or more medical purposes that performs those purposes without being part of a hardware medical device. The scope encompasses diagnostic and screening software, including artificial intelligence tools that analyze medical images and data, clinical decision support software that informs and drives clinical management, digital therapeutics that treat and manage disease, and monitoring and treatment planning software, running on general-purpose computing platforms and increasingly powered by artificial intelligence and machine learning. Leading products include the LumineticsCore autonomous diagnostic software for diabetic retinopathy, the Viz.ai and Aidoc clinical artificial intelligence triage and detection tools, and digital therapeutics such as those developed by WellDoc and others, and the market is defined by the International Medical Device Regulators Forum framework and regulated by the Food and Drug Administration, the European Union Medical Device Regulation, and aligned national frameworks. The contemporary market is shaped by the integration of artificial intelligence, the growth of digital therapeutics, and the maturation of regulatory pathways for software and adaptive algorithms.

Software as a Medical Device (SaMD) Market Key Growth Drivers

• Integration of artificial intelligence and machine learning into clinical software, with the Food and Drug Administration having authorized a large and growing number of artificial intelligence-enabled devices.
• Growth of digital therapeutics and software-based treatment for chronic, behavioral, and neurological conditions.
• Maturation of regulatory pathways for software and adaptive algorithms, including the predetermined change control plan for artificial intelligence-enabled software.
• Demand for diagnostic and clinical decision support that improves the accuracy, speed, and access of care.
• Growth of remote monitoring, telehealth, and connected care that software as a medical device supports.
• Rising burden of chronic disease and the demand for scalable software-based diagnosis, monitoring, and treatment.
• Adoption of cloud and general-purpose computing platforms that deliver software as a medical device at scale.

Key Companies in Software as a Medical Device (SaMD) Market

The leading participants in the software as a medical device market include the following:

• Koninklijke Philips N.V.
• Siemens Healthineers AG
• GE HealthCare Technologies Inc.
• Medtronic plc
• Aidoc Medical Ltd.
• Viz.ai, Inc.
• Digital Diagnostics Inc.
• HeartFlow, Inc.
• Cognoa, Inc.
• Huma Therapeutics Limited

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies relevant to the market assessment.

Software as a Medical Device (SaMD) Market Size

The following table summarizes the headline market metrics for the global software as a medical device market across the base year and the forecast horizon.

All market values are expressed in USD and represent DelveInsight estimates synthesized from primary and secondary research.

Factors Contributing to the Growth of the Software as a Medical Device (SaMD) Market

Market Drivers

Integration of Artificial Intelligence and Machine Learning into Clinical Software

The foundational driver of the software as a medical device market is the integration of artificial intelligence and machine learning into clinical software, which has transformed diagnosis, monitoring, and decision support. Artificial intelligence and machine learning enable software to analyze large volumes of medical data, including images, physiological signals, genetic data, and electronic health records, to detect patterns and conditions difficult for humans to detect, and the integration of these technologies into software as a medical device has revolutionized diagnostics, monitoring, treatment support, and decision-making. The Food and Drug Administration has authorized a large and growing number of artificial intelligence-enabled medical devices, with the authorized list expanding to exceed a thousand entries and double from earlier years, and the majority are software that analyzes images and data in radiology, cardiology, and other specialties. Artificial intelligence software detects and triages disease, prioritizes urgent findings, supports diagnosis, and recommends evidence-based actions, and its ability to learn from real-world use and improve performance makes it a rapidly expanding area of development. The transformation of clinical software by artificial intelligence, the authorization of artificial intelligence-enabled software, and the value of artificial intelligence in diagnosis and decision support drive the growth of the market. As artificial intelligence and machine learning are integrated into clinical software and as authorized artificial intelligence software expands, the market grows. The integration of artificial intelligence and machine learning into clinical software anchors the growth of the software as a medical device market across the forecast period.

Growth of Digital Therapeutics and Software-Based Treatment

The growth of digital therapeutics and software-based treatment is a defining driver that expands software as a medical device from diagnosis into treatment. Digital therapeutics are software that treats, manages, or prevents disease through evidence-based therapeutic interventions, and they have been developed and cleared for chronic, behavioral, and neurological conditions, including diabetes, substance use, and other disorders. Digital therapeutics integrate behavioral, cognitive, and lifestyle interventions with software delivery, treating conditions through applications that patients use on general-purpose devices, and cleared digital therapeutics deliver cognitive behavioral therapy, disease management, and neurological therapy. The growth of digital therapeutics is driven by the value of scalable, accessible, software-based treatment, the evidence of clinical efficacy, and the demand for treatment of chronic and behavioral conditions, and it expands software as a medical device from diagnosis and monitoring into treatment. Digital therapeutics complement or substitute for pharmacotherapy, extend treatment to underserved populations, and support the management of chronic and behavioral conditions, and their development and clearance expand the market. As digital therapeutics grow and as software-based treatment is developed and cleared, the software as a medical device market expands into treatment. The growth of digital therapeutics and software-based treatment sustains demand for software as a medical device across the forecast period.

Maturation of Regulatory Pathways for Software and Adaptive Algorithms

The maturation of regulatory pathways for software and adaptive algorithms reduces uncertainty and enables the development and iterative improvement of software as a medical device. Regulators have developed frameworks and pathways specifically for software as a medical device, with the International Medical Device Regulators Forum establishing a risk categorization framework and the Food and Drug Administration developing tailored policies, pathways, and guidance for software and artificial intelligence. The Food and Drug Administration finalized the predetermined change control plan guidance, which enables manufacturers of artificial intelligence-enabled software to pre-authorize planned modifications and to improve their software iteratively without a new marketing submission for each change, addressing the challenge of adaptive and learning algorithms. The clearance pathways, including premarket notification, de novo classification, and premarket approval, and the guidance on software, artificial intelligence, good machine learning practice, and change control, provide a maturing framework for the development and authorization of software. The maturation of regulatory pathways reduces the uncertainty of software development, enables the iterative improvement of adaptive algorithms, and provides a clearer route to market, encouraging investment and development. As regulatory pathways mature and as the predetermined change control plan enables iterative improvement, the development and authorization of software as a medical device grow. The maturation of regulatory pathways for software and adaptive algorithms sustains the growth of the software as a medical device market across the forecast period.

Demand for Diagnostic and Clinical Decision Support

The demand for diagnostic and clinical decision support that improves the accuracy, speed, and access of care drives the adoption of software as a medical device. Healthcare faces the challenges of diagnostic error, clinician shortage, workload, and the demand for timely and accurate diagnosis and decision-making, and software as a medical device provides diagnostic support, triage, and clinical decision support that improve the accuracy, speed, and consistency of care. Diagnostic and screening software analyzes images and data to detect and characterize disease, triage software prioritizes urgent cases such as stroke and other time-critical conditions, and clinical decision support software informs and drives clinical management, improving outcomes and efficiency. The value of software in improving diagnostic accuracy, accelerating the identification of urgent conditions, extending specialist capability, and supporting clinicians drives its adoption, and the demand for scalable diagnostic and decision support in the face of workforce constraints reinforces this. Software as a medical device addresses the demand for accurate, timely, and scalable diagnosis and decision support, and its clinical and operational value drives adoption. As healthcare seeks to improve diagnostic accuracy, speed, and access and to support clinicians, demand for diagnostic and clinical decision support software grows. The demand for diagnostic and clinical decision support sustains demand for software as a medical device across the forecast period.

Growth of Remote Monitoring, Telehealth, and Connected Care

The growth of remote monitoring, telehealth, and connected care drives the adoption of the software as a medical device that supports care outside the clinic. The shift toward remote monitoring, telehealth, and home-based and connected care, accelerated in recent years, generates demand for software that monitors patients, analyzes data, and supports diagnosis and treatment remotely, and software as a medical device provides the intelligence that turns remote and connected data into clinical insight and action. Software analyzes the data from connected devices and remote monitoring, detects deterioration and events, supports remote diagnosis and decision-making, and delivers digital therapeutics and monitoring to patients at home. The growth of remote and connected care, driven by cost, access, and patient preference, generates demand for the software that analyzes remote data and supports remote care, and software as a medical device is central to the intelligence of connected and remote care. The integration of software as a medical device with remote monitoring, telehealth, and connected devices extends care to the home and supports the management of patients remotely. As remote monitoring, telehealth, and connected care grow, demand for the software as a medical device that supports them grows. The growth of remote monitoring, telehealth, and connected care sustains demand for software as a medical device across the forecast period.

Rising Burden of Chronic Disease and Demand for Scalable Software

The rising burden of chronic disease and the demand for scalable software-based diagnosis, monitoring, and treatment drive the adoption of software as a medical device. The rising prevalence of chronic conditions such as diabetes, cardiovascular disease, and neurological and behavioral disorders, driven by the aging population and lifestyle factors, increases the demand for scalable and accessible diagnosis, monitoring, and treatment, and software as a medical device provides scalable software-based diagnosis, monitoring, and treatment that can reach large populations. Software as a medical device diagnoses and screens for chronic conditions, monitors and manages chronic disease, and delivers digital therapeutics that treat and manage chronic and behavioral conditions, extending care to large and underserved populations at scale. The burden of chronic disease, the cost and capacity constraints of managing it, and the demand for scalable and accessible care drive the adoption of software that provides diagnosis, monitoring, and treatment at scale. The scalability, accessibility, and cost-effectiveness of software-based care make it valuable for the management of the growing burden of chronic disease. As chronic disease rises and as healthcare seeks scalable and accessible software-based care, demand for software as a medical device grows. The rising burden of chronic disease and the demand for scalable software sustain demand for software as a medical device across the forecast period.

Adoption of Cloud and General-Purpose Computing Platforms

The adoption of cloud and general-purpose computing platforms delivers software as a medical device at scale and drives the growth of the market. Software as a medical device runs on general-purpose computing platforms, including smartphones, tablets, computers, and cloud servers, and the adoption of cloud computing and the ubiquity of general-purpose devices enable the deployment of software at scale without dedicated hardware. Cloud deployment provides the scalability, computing power, and connectivity that artificial intelligence and data-intensive software require, enables the delivery of software across sites and to patients, and supports the updating and improvement of software; the ubiquity of smartphones and computers provides the platform for digital therapeutics and monitoring. The delivery of software on cloud and general-purpose platforms lowers the barrier to deployment, enables scale and accessibility, and provides the computing power for artificial intelligence, and it makes software as a medical device widely deployable. The adoption of cloud and general-purpose computing platforms enables the scalable, accessible, and updatable delivery of software as a medical device. As cloud and general-purpose platforms are adopted and as they deliver software at scale, the deployment and adoption of software as a medical device grow. The adoption of cloud and general-purpose computing platforms sustains demand and reinforces the leadership of cloud deployment across the forecast period.

Market Restraints

The software as a medical device market faces several interrelated restraints that temper its growth. The foremost is the complexity and burden of regulation, since software as a medical device is regulated as a medical device requiring clearance or approval, clinical evidence, and quality and lifecycle management, and the cost, time, and complexity of regulatory submission and compliance, particularly for higher-risk software and across multiple jurisdictions, are substantial and can be a barrier, especially for smaller developers. 

The challenge of regulating adaptive and learning algorithms persists, since artificial intelligence software that learns and changes challenges the traditional model of device authorization, and while the predetermined change control plan addresses this, its adoption is still developing, and fully autonomous continuous learning is not yet permitted without predetermined protocols and validation. Reimbursement is a significant challenge, since the reimbursement of software as a medical device and digital therapeutics is limited, evolving, and inconsistent, and the absence of established reimbursement pathways constrains the business model and adoption. 

Clinical validation and evidence generation are demanding and costly, since software must demonstrate safety, effectiveness, and clinical benefit, and the generation of clinical evidence requires studies, time, and investment. Clinical adoption and integration face barriers of clinician acceptance, workflow integration, integration with electronic health records and clinical systems, and the demonstration of value, and the adoption of software into clinical practice can be slow. Data privacy, security, and quality obligations, and the risk of bias and the requirement for performance across populations, add compliance burden and risk. Liability and the assignment of responsibility for software-driven decisions raise legal and clinical questions. Together, these factors moderate the pace and scope of adoption and require developers to demonstrate regulatory compliance, clinical evidence, reimbursement, and value to sustain growth.

Software as a Medical Device (SaMD) Market Segment Analysis

The global software as a medical device market is segmented by type (diagnostic and screening software, clinical decision support software, digital therapeutics, and monitoring and treatment planning software), by application (radiology and medical imaging, cardiology, neurology, ophthalmology, and others), by deployement (cloud-based and on premise and embedded), and by end-users (hospitals, patients and consumers, diagnostic and imagaing centers,, and others) by geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Type

Dominant Subsegment: Diagnostic and Screening Software.

The diagnostic and screening software category is expected to dominate the market. The diagnostic and screening software segment accounted for a 42% share of the software as a medical device market in 2025. Diagnostic and screening software, including the artificial intelligence tools that analyze medical images and data to detect, characterize, and triage disease, is the leading type because it is the largest and most mature category of software as a medical device, comprising the majority of authorized artificial intelligence-enabled software and addressing the high-value applications of diagnosis and screening. The dominance of the segment reflects the maturity and volume of diagnostic artificial intelligence, the concentration of authorized software in diagnosis and screening, and the clinical and commercial value of accurate and scalable diagnosis. Diagnostic and screening software analyzes images and data in radiology, cardiology, ophthalmology, pathology, and other specialties to detect and triage disease, and the majority of authorized artificial intelligence-enabled devices are diagnostic software. The maturity of diagnostic artificial intelligence, the volume of authorized diagnostic software, and the value of diagnosis and screening drive the segment. While clinical decision support, digital therapeutics, and monitoring software are important and growing types, the maturity, volume, and value of diagnostic and screening software sustain the leadership of the diagnostic and screening software segment across the forecast period.

By Application

Dominant Subsegment: Radiology and Medical Imaging.

The radiology and medical imaging category is expected to dominate the market. The radiology and medical imaging segment accounted for a 34% share of the software as a medical device market in 2025. Radiology and medical imaging is the leading application because it is the most developed and highest-volume area of software as a medical device, with the majority of artificial intelligence-enabled software analyzing medical images to detect, characterize, and triage disease. The dominance of the segment reflects the concentration of artificial intelligence software in imaging, the volume and value of imaging analysis, and the maturity of imaging artificial intelligence. Software analyzes radiological images, including computed tomography, magnetic resonance, and other modalities, to detect and triage conditions such as stroke, fractures, nodules, and other findings, prioritizing urgent cases and supporting radiologists; the majority of authorized artificial intelligence software is in radiology and imaging. The volume of imaging, the value of imaging analysis and triage, and the maturity of imaging artificial intelligence drive the segment. While cardiology, ophthalmology, neurology, oncology, and other applications are significant and growing, the concentration, volume, and maturity of radiology and medical imaging sustain the leadership of the radiology and medical imaging segment across the forecast period.

By Deployment

Dominant Subsegment: Cloud-Based.

The cloud-based category is expected to dominate the market. The cloud-based segment accounted for a 62% share of the software as a medical device market in 2025. Cloud-based deployment, in which software as a medical device runs on cloud infrastructure, is the leading deployment mode because it provides the scalability, computing power, and connectivity that artificial intelligence and data-intensive software require and enables the delivery of software across sites and to patients. The dominance of the segment reflects the migration of software to the cloud, the computing power that cloud provides for artificial intelligence, and the scalability and connectivity of cloud delivery. Cloud deployment provides the computing power for artificial intelligence analysis, enables the delivery and updating of software across sites and to patients, and supports the scale and connectivity of software as a medical device. Cloud-based software analyzes data, delivers results, and connects to clinical systems and devices. The computing power for artificial intelligence, the scalability and connectivity of cloud, and the support for updating and delivery drive the cloud-based segment. While on-premise and embedded deployment remain relevant for certain settings and latency or privacy requirements, the computing power, scalability, and connectivity of cloud sustain the leadership of the cloud-based segment across the forecast period.

By End-User

Dominant Subsegment: Hospitals and Clinics.

The hospitals and clinics category is expected to dominate the market. The hospitals and clinics segment accounted for a 54% share of the software as a medical device market in 2025. Hospitals and clinics are the leading end-user because they are the principal sites of diagnosis, imaging, and clinical care where diagnostic, triage, and clinical decision support software is deployed, and they represent the largest source of demand for software as a medical device. The dominance of the segment reflects the concentration of diagnosis, imaging, and clinical care in hospitals and clinics, the deployment of diagnostic and decision support software in clinical settings, and the value of software in improving clinical accuracy and efficiency. Hospitals and clinics deploy diagnostic and screening software, triage software, and clinical decision support software in radiology, cardiology, emergency, and other departments to improve the accuracy, speed, and efficiency of care, and they are the principal purchasers and users of clinical software as a medical device. The concentration of clinical care and imaging, the deployment of software in clinical workflows, and the value of software to providers concentrate demand in hospitals and clinics. While patients and consumers, who use digital therapeutics and monitoring software, and other end-users are important and growing, particularly for digital therapeutics, the concentration of clinical care and the deployment of diagnostic and decision support software sustain the leadership of the hospitals and clinics segment across the forecast period, and it shapes the direction of the market.

Software as a Medical Device (SaMD) Market Region Analysis

Dominant Region: North America

North America accounted for a 45% share of the global software as a medical device market in 2025, representing the highest regional market share globally. The leadership of the region reflects the advanced regulatory framework for software and artificial intelligence, the concentration of clinical artificial intelligence and digital health companies, the advanced adoption of clinical software, and the strength of research and investment. The United States is the largest national market, supported by the Food and Drug Administration framework and pathways for software and artificial intelligence-enabled devices, the authorization of a large and growing number of artificial intelligence-enabled devices, the concentration of clinical artificial intelligence, imaging, and digital therapeutics companies, and the advanced adoption of clinical software. The Food and Drug Administration has developed tailored policies, pathways, and guidance for software as a medical device, including the predetermined change control plan for artificial intelligence-enabled software, and the advanced healthcare and technology ecosystem supports the development and adoption of software. The leading clinical artificial intelligence, imaging, and digital therapeutics companies are headquartered or operate extensively in the region, and the adoption of diagnostic, triage, and decision support software is advanced. The advanced regulatory framework, the concentration of companies, the adoption of software, and the strength of investment reinforce the leadership of the region. The combination of regulatory maturity, company concentration, adoption, and investment sustains the position of North America as the largest regional market across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate through 2034. The region combines large and growing populations, the expansion of healthcare and digital infrastructure, the growth of artificial intelligence and digital health, and the increasing adoption of clinical software, which drives the fast growth of the market. China, Japan, India, and South Korea are the principal national markets, supported by the growth of healthcare investment and digital infrastructure, the development of artificial intelligence and digital health industries, the rising burden of chronic disease, and the increasing adoption of diagnostic and clinical software. The growth of healthcare and digital infrastructure, the development of artificial intelligence and digital health, and the adoption of clinical software enlarge the demand for software as a medical device. As healthcare and digital infrastructure expand, as artificial intelligence and digital health develop, and as clinical software is adopted, the region increases its adoption from a growing base, and the scale of the population and the growth of digital health create substantial long-term demand. The combination of population scale, infrastructure expansion, artificial intelligence and digital health growth, and software adoption positions Asia-Pacific as the fastest-growing regional market, and it attracts investment and commercial focus from the leading global and regional companies.

Regional Commentary

North America

North America leads the market, supported by the advanced regulatory framework for software and artificial intelligence, the concentration of clinical artificial intelligence and digital health companies, the advanced adoption of clinical software, and the strength of research and investment. The United States dominates the region through the Food and Drug Administration framework for software and artificial intelligence, the authorization of artificial intelligence-enabled devices, and the concentration of companies. The advanced ecosystem and adoption sustain demand.

Europe

Europe is a substantial market shaped by the regulation of software under the European Union Medical Device Regulation, which classifies standalone software with a medical purpose as a medical device, the adoption of clinical software, and the presence of medical technology and digital health companies. Germany, the United Kingdom, France, Italy, and Spain are the principal national markets, supported by the adoption of clinical artificial intelligence and digital health, the regulation of software as a medical device, and the emerging artificial intelligence regulation. Demand is sustained by the adoption of diagnostic and clinical software and the growth of digital health.

Asia-Pacific

Asia-Pacific is the fastest-growing region, driven by large and growing populations, the expansion of healthcare and digital infrastructure, the growth of artificial intelligence and digital health, and the increasing adoption of clinical software across China, Japan, India, and South Korea. Infrastructure expansion, artificial intelligence and digital health growth, and software adoption sustain rapid growth, and the region attracts commercial focus from the leading global and regional companies.

Rest of World

The Rest of World, spanning Latin America, the Middle East, and Africa, represents an emerging opportunity as healthcare and digital infrastructure expand and as clinical software is adopted. Growth is supported by the growth of digital health, the adoption of diagnostic and clinical software, and the expansion of access, though adoption and regulatory maturity vary by market. Companies pursue these markets through cloud-delivered software suited to expanding digital health.

Software as a Medical Device (SaMD) Market Competitive Landscape

The global software as a medical device market is classified as Fragmented. A large and diverse group of participants competes across the categories of software as a medical device, including medical technology and imaging companies, clinical artificial intelligence specialists, digital therapeutics companies, and health technology companies, and no single participant holds a dominant share of the diverse and rapidly evolving market. Competition centers on the clinical performance and validation of the software, the regulatory clearance and pathway, the integration with clinical workflow and systems, the breadth of clinical applications, the intelligence of the artificial intelligence, reimbursement, and clinical adoption; clearances, launches, and investment intensify the contest. The competitive landscape is evaluated across the following dimensions:

• Market concentration: Fragmented, with medical technology and imaging companies, clinical artificial intelligence specialists, digital therapeutics companies, and health technology companies, and no single participant holding a dominant share of the diverse and rapidly evolving market.
• Leading players: Philips, Siemens Healthineers, GE HealthCare, and Medtronic lead among the medical technology and imaging companies; Aidoc, Viz.ai, Digital Diagnostics, and HeartFlow lead in clinical artificial intelligence, and Cognoa, Huma, and digital therapeutics companies contest the treatment and platform categories.
• Geographic reach: The medical technology and imaging companies operate globally, and clinical artificial intelligence and digital therapeutics specialists expand from their home markets, with concentration in North America and Europe.
• Product portfolio strength: Competitive advantage rests on the clinical performance and validation of the software, the breadth of clinical applications, the integration with imaging and clinical systems, and the intelligence and adaptability of the artificial intelligence.
• Pipeline strength: Development is concentrated in artificial intelligence diagnostic and triage software, digital therapeutics, clinical decision support, and the expansion of clinical applications and indications.
• Strategic partnerships: Collaboration spans integration with imaging and electronic health record systems, partnerships with health systems and pharmaceutical companies, and alliances that extend clinical validation, distribution, and reimbursement.
• M&A activity: Consolidation has shaped the field, with medical technology and imaging companies acquiring clinical artificial intelligence and software companies and platforms consolidating clinical artificial intelligence, alongside continued investment and consolidation.
• Innovation focus: Innovation is shifting toward advanced artificial intelligence diagnostic and triage software, digital therapeutics, adaptive and learning algorithms with change control, and the integration and platforming of clinical software.
• Regulatory standing: Clearance and authorization by the Food and Drug Administration, conformity under the European Union Medical Device Regulation, alignment with the International Medical Device Regulators Forum framework, and the adoption of the predetermined change control plan for adaptive software are decisive competitive credentials and a principal axis of competition among the leaders.

Software as a Medical Device (SaMD) Market Recent Developmental Activities

In 2021, the Food and Drug Administration published its artificial intelligence and machine learning software as a medical device action plan, setting out a framework for the oversight of artificial intelligence and machine learning-based software. Strategic significance: the action plan advanced the tailored regulation of artificial intelligence software and shaped the development of subsequent guidance.

In June 2023, Huma Therapeutics Limited received Food and Drug Administration Class II clearance for a disease-agnostic software as a medical device platform, enabling the configuration of regulated software across conditions. Strategic significance: the clearance advanced the platform model of software as a medical device and enabled the rapid configuration of regulated software.

In May 2024, the Food and Drug Administration authorized an artificial intelligence-enabled wearable electrocardiogram system that adapts to a patient's heart rhythm to improve detection accuracy. Strategic significance: the authorization advanced adaptive artificial intelligence in monitoring software and demonstrated the application of learning algorithms.

In December 2024, the Food and Drug Administration published final guidance on the predetermined change control plan for artificial intelligence-enabled device software functions, with implementation details added in August 2025. Strategic significance: the guidance enabled manufacturers to pre-authorize planned modifications and to improve artificial intelligence software iteratively, addressing the challenge of adaptive algorithms.

In February 2025, Aidoc Medical Ltd. received Food and Drug Administration clearance for a computer-aided triage tool for the detection and triage of rib fractures, extending its clinical artificial intelligence portfolio. Strategic significance: the clearance advanced artificial intelligence triage software and reinforced the position of a leading clinical artificial intelligence company.

In 2024 and 2025, the Food and Drug Administration expanded its artificial intelligence-enabled medical device list to exceed a thousand authorized devices, double the earlier count, with the majority classified as software cleared through the premarket notification pathway. Strategic significance: the expansion reflected the rapid growth and authorization of artificial intelligence software as a medical device.

In 2024 and 2025, Viz.ai, Inc. advanced its clinical artificial intelligence platform for the detection and triage of stroke and other time-critical conditions and the coordination of care. Strategic significance: the developments reinforced the position of a leading clinical artificial intelligence company in time-critical triage and care coordination.

In 2024 and 2025, Digital Diagnostics Inc. advanced its autonomous diagnostic software, including the diagnosis of diabetic retinopathy from retinal images without specialist interpretation. Strategic significance: the developments reinforced the position of a pioneer of autonomous diagnostic software and the highest-autonomy category of software as a medical device.

In 2024 and 2025, the medical technology and imaging companies including Koninklijke Philips N.V., Siemens Healthineers AG, and GE HealthCare Technologies Inc. advanced their artificial intelligence and clinical software portfolios, integrating software as a medical device with imaging and clinical systems. Strategic significance: the developments reinforced the role of the major medical technology companies in clinical software and the integration of artificial intelligence with imaging.

In 2024 and 2025, digital therapeutics companies advanced software-based treatments for chronic, behavioral, and neurological conditions, navigating clearance, evidence, and reimbursement. Strategic significance: the developments advanced software-based treatment and the digital therapeutics category despite reimbursement challenges.

In 2024 and 2025, the European Union advanced the regulation of software as a medical device under the Medical Device Regulation and the emerging artificial intelligence regulation, classifying and regulating clinical software. Strategic significance: the developments shaped the regulation of software as a medical device in Europe and the layering of artificial intelligence regulation on device regulation.

In 2024 and 2025, the leading participants advanced artificial intelligence diagnostic and triage software, digital therapeutics, adaptive algorithms with change control, and clinical integration across software as a medical device. Strategic significance: the convergence of the leaders on artificial intelligence, digital therapeutics, adaptive software, and integration confirmed these as the defining axes of competition and signaled a market advancing toward intelligent, adaptive, and clinically integrated software as a medical device.

Software as a Medical Device (SaMD) Market Segmentation

Software as a Medical Device (SaMD) Market Assessment by Type

• Diagnostic and Screening Software
• Clinical Decision Support Software
• Digital Therapeutics
• Monitoring and Treatment Planning Software

Software as a Medical Device (SaMD) Market Assessment by Application

• Radiology and Medical Imaging
• Cardiology
• Neurology
• Ophthalmology
• Others

Software as a Medical Device (SaMD) Market Assessment by Deployment

• Cloud-Based
• On-Premise and Embedded

Software as a Medical Device (SaMD) Market Assessment by End-User

• Hospitals and Clinics
• Patients and Consumers
• Diagnostic and Imaging Centers
• Others

Software as a Medical Device (SaMD) Market Assessment by Geography

• North America

• United States Software as a Medical Device Market Size in USD million (2023-2034)
• Canada Software as a Medical Device Market Size in USD million (2023-2034)
• Mexico Software as a Medical Device Market Size in USD million (2023-2034)

• Europe

• Germany Software as a Medical Device Market Size in USD million (2023-2034)
• United Kingdom Software as a Medical Device Market Size in USD million (2023-2034)
• France Software as a Medical Device Market Size in USD million (2023-2034)
• Italy Software as a Medical Device Market Size in USD million (2023-2034)
• Spain Software as a Medical Device Market Size in USD million (2023-2034)
• Rest of Europe Software as a Medical Device Market Size in USD million (2023-2034)

• Asia-Pacific

• China Software as a Medical Device Market Size in USD million (2023-2034)
• Japan Software as a Medical Device Market Size in USD million (2023-2034)
• India Software as a Medical Device Market Size in USD million (2023-2034)
• Australia Software as a Medical Device Market Size in USD million (2023-2034)
• South Korea Software as a Medical Device Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Software as a Medical Device Market Size in USD million (2023-2034)

• Rest of the World

• Middle East Software as a Medical Device Market Size in USD million (2023-2034)
• Africa Software as a Medical Device Market Size in USD million (2023-2034)
• South America Software as a Medical Device Market Size in USD million (2023-2034)

Software as a Medical Device (SaMD) Market Recent Industry Trends and Milestones (2023-2026)

Software as a Medical Device (SaMD) Market Startup Funding and Investment Trends

Investment in the software as a medical device field has concentrated on technologies that bring artificial intelligence and software to diagnosis, monitoring, and treatment, namely artificial intelligence diagnostic and triage software, digital therapeutics, clinical decision support, and adaptive and autonomous software. Because the market is fragmented across medical technology, clinical artificial intelligence, and digital therapeutics companies, innovators pursue differentiated diagnostic, treatment, or platform software that serves defined clinical needs or that a larger company can absorb. The table below summarizes representative companies advancing the next generation of software as a medical device.

Capital formation in this field is shaped by the presence of large medical technology and imaging companies and a broad ecosystem of clinical artificial intelligence and digital therapeutics companies, so investors have favored companies that introduce differentiated artificial intelligence diagnostic and triage software, digital therapeutics, or autonomous and platform software that serves defined clinical needs or that a larger company can absorb. Artificial intelligence diagnostic and triage software is a clear thesis, improving the accuracy and speed of diagnosis and the prioritization of urgent conditions. Digital therapeutics constitute a second thesis, delivering software-based treatment, and adaptive and autonomous software a third, improving iteratively and diagnosing without specialists. The archetypal outcome is acquisition by a medical technology, imaging, or health company seeking to add software, exemplified by the acquisition of clinical artificial intelligence companies, or growth into a clinical software company, though reimbursement and clinical adoption are the central challenges. The principal risks are the regulatory burden, the reimbursement of software and digital therapeutics, the clinical validation and adoption required, and the scale and reach of the large medical technology companies. 

Key Takeaways from the Software as a Medical Device (SaMD) Market Report Study

• Market size analysis for the current software as a medical device market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key software, artificial intelligence, and regulatory developments, clearances, partnerships, and investments that happened over the last 3 years.
• Key companies dominating the global software as a medical device market.
• Various opportunities available for competitors in the software as a medical device market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current software as a medical device market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for software as a medical device market growth in the future?

Target audience who can benefit from this software as a medical device market report study

• Software as a medical device, clinical artificial intelligence, and digital therapeutics providers
• Research organizations and consulting companies
• Software as a medical device-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Hospitals, health systems, and medical technology companies dealing in clinical software
• Various end-users who want to know more about the software as a medical device market and the latest technological developments in the software as a medical device market.